We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B Turnover 46.34%
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+4.73%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$1.11B
AUM Growth
+$59.7M
Cap. Flow
+$37M
Cap. Flow %
3.34%
Top 10 Hldgs %
63.03%
Holding
52
New
19
Increased
6
Reduced
15
Closed
2
Avg Time Held Equity + Options
0.6 years
Top 10 Avg Time Held Equity + Options
1.3 years
Top 20 Avg Time Held Equity + Options
0.8 years
Avg Time Held Equity only
0.6 years
Top 10 Avg Time Held Equity only
1.3 years
Top 20 Avg Time Held Equity only
0.8 years

Top Buys

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$57.2M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$26.2M
3
AKCA
Akcea Therapeutics Inc
AKCA
+$22.8M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$20.7M
5
RUBY
Rubius Therapeutics, Inc
RUBY
+$13.5M

Top Sells

Rank Stock Value
1
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$55.8M
2
ASND icon
Ascendis Pharma A/S
ASND
+$25.9M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$20.9M
4
SGMO icon
SANGAMO THERAPEUTICS INC
SGMO
+$17.7M
5
WVE icon
Wave Life Sciences
WVE
+$16.6M

Sector Composition

Rank Sector Weight
1 Healthcare 87.05%
2 Miscellaneous 12.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ABUS icon
26
Arbutus Biopharma
ABUS
$840M
$11.6M 1.05%
+1,231,800
New +$12.2M
2018 Q3
0 quarters
IRWD icon
27
CALL
Ironwood Pharmaceuticals
IRWD
$593M
$10.5M 0.94%
677,714
-11,940
-2% -$189K
2017 Q3
4 quarters
SPRO icon
28
Spero Therapeutics
SPRO
$67M
$9.38M 0.85%
+892,741
New +$10.4M
2018 Q3
0 quarters
IMDZ
29
DELISTED
Immune Design Corp.
IMDZ
$7.74M 0.7%
2,241,900
-2,195,700
-49% -$8.24M
2017 Q4
3 quarters
ZLAB icon
30
Zai Lab
ZLAB
$2.66B
$6.82M 0.61%
+350,000
New +$7.59M
2018 Q3
0 quarters
NGNE icon
31
Neurogene
NGNE
$482M
$6.64M 0.6%
113,294
+55,794
+97% +$3.29M
2018 Q2
1 quarter
ELAN icon
32
Elanco Animal Health
ELAN
$12B
$6.63M 0.6%
+190,000
New +$6.68M
2018 Q3
0 quarters
SGMO icon
33
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$5.82M 0.52%
343,231
-1,166,440
-77% -$17.7M
2018 Q2
1 quarter
ACHN
34
DELISTED
Achillion Pharmaceuticals
ACHN
$5.76M 0.52%
1,564,080
-2,323,327
-60% -$6.92M
2017 Q4
3 quarters
ASMB icon
35
CALL
Assembly Biosciences
ASMB
$409M
$5.5M 0.5%
12,342
– –
2018 Q2
1 quarter
MRSN icon
36
DELISTED
Mersana Therapeutics
MRSN
$4.96M 0.45%
+19,825
New +$6.64M
2018 Q3
0 quarters
KDMN
37
DELISTED
Kadmon Holdings, Inc.
KDMN
$4.95M 0.45%
1,480,870
-1,019,130
-41% -$3.61M
2018 Q2
1 quarter
IONS icon
38
Ionis Pharmaceuticals
IONS
$7.26B
$3.73M 0.34%
+72,326
New +$3.4M
2018 Q3
0 quarters
TRAW icon
39
Traws Pharma
TRAW
$5.98M
$3.67M 0.33%
1,333
– –
2018 Q2
1 quarter
TECX icon
40
Tectonic Therapeutic
TECX
$412M
$3.56M 0.32%
+5,721
New +$2.54M
2018 Q3
0 quarters
JNCE
41
CALL
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$3.23M 0.29%
+497,400
New +$3.7M
2018 Q3
0 quarters
CRVS icon
42
Corvus Pharmaceuticals
CRVS
$813M
$3.02M 0.27%
351,401
-98,999
-22% -$990K
2017 Q2
5 quarters
WVE icon
43
Wave Life Sciences
WVE
$631M
$2.24M 0.2%
44,841
-368,030
-89% -$16.6M
2017 Q3
4 quarters
CNST
44
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$1.88M 0.17%
+280,000
New +$2.67M
2018 Q3
0 quarters
FTSV
45
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$1.48M 0.13%
+99,000
New +$1.48M
2018 Q3
0 quarters
CHMA
46
DELISTED
Chiasma, Inc. Common Stock
CHMA
$1.37M 0.12%
+379,753
New +$794K
2018 Q3
0 quarters
INFI
47
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.25M 0.11%
462,068
+50,068
+12% +$104K
2018 Q2
1 quarter
APTX
48
DELISTED
Aptinyx Inc. Common Stock
APTX
$1.19M 0.11%
41,037
– –
2018 Q2
1 quarter
ARVN icon
49
Arvinas
ARVN
$468M
$844K 0.08%
+50,000
New +$823K
2018 Q3
0 quarters
PHXM
50
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$590K 0.05%
6,957
-8,439
-55% -$879K
2018 Q2
1 quarter
1
2
3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q3 2018 Portfolio in Review

As of Q3 2018, EcoR1 Capital held 52 positions worth $1.11B, up 5.7% from $1.05B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

EcoR1 Capital deployed $37M of net new capital in Q3 2018, opening 19 new positions and adding to 6 existing holdings. Its largest new stake was Spark Therapeutics, Inc. Common Stock: 837,048 shares worth $45.7M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 87% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $25.9M trimmed.

  • EcoR1 Capital's largest Q3 2018 buy was Spark Therapeutics, Inc. Common Stock: 837,048 shares worth $45.7M.
  • EcoR1 Capital added most to Dicerna Pharmaceuticals, Inc. in Q3 2018, an estimated $12.2M increase.
  • EcoR1 Capital's biggest Q3 2018 reduction was Ascendis Pharma A/S, cutting an estimated $25.9M.
  • EcoR1 Capital fully exited Madrigal Pharmaceuticals in Q3 2018, selling an estimated $55.8M.
  • EcoR1 Capital's ten largest holdings make up 63% of its $1.11B portfolio in Q3 2018.
  • EcoR1 Capital opened 19 new positions and closed 2 in Q3 2018.
  • EcoR1 Capital's portfolio value rose 5.7% quarter-over-quarter to $1.11B.

Based on EcoR1 Capital's 13F filing for Q3 2018, filed 14 Nov 2018.